The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial

Tiago Lemos Cerqueira   ^{1, 2, 3 *} , MPH, MD ;   Armando Fartolino Guerrero   ^{2, 4} , MD ;   Clara Krystal Pérez Fermin   ^{2, 5} , MD ;   Ricardo Wang   ^{2, 6} , MD ;   Evelin Elfriede Balbino   ^{2, 7} , PharmD ;   Janis L Breeze   ^{8, 9} , MPH, PhD ;   Paola Gonzalez Mego   ^{2, 10} , MD ;   Daniele Argentina Silva   ^{2, 11} , MD ;   Walid Ezzeldin Omer   ^{2, 12} , MD ;   Nathalie Monique Vandevelde   ^{2, 13 *} , PharmD, PhD

¹ Betim Nephrology Unit, Associaçao Evangélica Beneficente de Minas Gerais, Belo Horizonte, Brazil

² Harvard TH Chan School of Public Health, Harvard University, Boston, MA, United States

³ Dresden International University, Dresden, Germany

⁴ Family Health Strategy, São Paulo Municipal Health Department, São Paulo, Brazil

⁵ Hematology-Oncology Unit, Hospital Infantil Regional Universitario Dr Arturo Grullón, Santiago De Los Caballeros, Dominican Republic

⁶ Cardiology Department, Santa Casa de Belo Horizonte, Unimed Belo Horizonte, Belo Horizonte, Brazil

⁷ Agência Nacional de Vigilância Sanitária, Brasilia, Brazil

⁸ Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, United States

⁹ Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Tufts University, Boston, MA, United States

¹⁰ Suiza Laboratory, Lima, Peru

¹¹ Faculdades Souza Marques, Rio de Janeiro, Brazil

¹² Hearing & Balance Unit, Hamad Medical Corporation, Doha, Qatar

¹³ Department of Quality of Medical Laboratories, Scientific Institute of Public Health, Brussels, Belgium

*these authors contributed equally